Skip to main content

Support for clinical trial capacity platform for sleeping sickness in Africa

Objective

Human African trypanosomiasis (HAT), known as sleeping sickness, is fatal if left untreated and a most neglected disease in Africa. An estimated 350,000 people are infected in 36 countries, the majority living in Angola, DRC, Uganda, Sudan and RoC. New di agnostics and treatments are urgently needed. Diagnostics require invasive methods and lack sensitivity and specificity. Drugs in use are old, toxic, losing efficacy, and require prolonged therapies. For over forty years, negligible clinical research has been done for new HAT treatments; thus, clinical research infrastructure and professional capacity in disease endemic countries is extremely limited. With new treatments in the pipeline, constraints in clinical evaluation and registration of new interve ntions for HAT must be urgently addressed. In August 2005, DNDi sponsored a regional workshop on HAT Clinical Trial Capacity that brought together endemic country HAT disease specialists and European clinical research and disease experts. This initial me eting resulted in the formation of a regional group who will work together to determine and implement a strategy to create sustainable regional and national clinical trial capacity for HAT. The present proposal seeks specific support for the primary acti vities of this group, which will include: HAT clinical trial methodology development Strengthening & harmonising regulatory practices throughout the region Developing strategies for national policy change Targeted HAT clinical trial capacity stren gthening Implementation will be through north-south and south-south exchange of expertise and best practice, specific training and workshops, and concurrent participation in clinical studies. Support to this project will enable the disease endemic count ries to conduct quality multicenter scale clinical trials in a timely manner with the ultimate aim of getting improved treatments registered and to patients as soon as possible.

Field of science

  • /medical and health sciences/clinical medicine/psychiatry/sleep disorders

Call for proposal

FP6-2002-INCO-DEV/SSA-1
See other projects for this call

Funding Scheme

SSA - Specific Support Action

Coordinator

DRUGS FOR NEGLECTED DISEASES INITIATIVE
Address
15, Chemin Louis-dunant
Geneva
Switzerland

Participants (6)

PROGRAMME NATIONALE DE LUTTE CONTRE LA TRYPANOSOMIASE HUMAINE AFRICAINE
Democratic Republic of the Congo
Address
Avenue De Justice 123A
Kinshasa-gombe
INSTITUTO DE COMBATE E CONTROLO DAS TRIPANOSSOMIASES
Angola
Address
168 Rua Cmdt. Kuenha
Luanda
PROGRAMME NATIONAL DE LUTTE CONTRE LA TRYPANOSOMIASE
Congo
Address

Brazzaville
COORDINATION OFFICE FOR THE CONTROL OF TRYPANOSOMIASIS IN UGANDA
Uganda
Address
Buganda Road Plot 76-78 Wandegeya-
Kampala
NATIONAL RESEARCH CENTER
Sudan
Address

Khartoum
SWISS TROPICAL INSTITUTE
Switzerland
Address
Socinstrasse 57
Basel